CryoSurgery, Inc. appears in FDA device records as an applicant for Class II cryosurgical units and accessories under product codes GEH and MLY. The company's own website presents it as a provider of cryosurgical solutions for medical and veterinary professionals, describing its devices as an alternative to traditional liquid nitrogen methods for removing warts and skin lesions. FDA records linked by MedtechLedger show a sequence of clearances spanning late 2024 through 2026, covering both over-the-counter wart and skin tag removers and a vapocoolant device. The profile below separates what the filings establish about the applicant and its products from what remains undocumented. [3][5][6][9]

The applicant and its regulatory identity

FDA clearance letters identify CryoSurgery, Inc. at 5829 Old Harding Pike, Nashville, Tennessee, with Ronald McDow listed as CEO and Medical Director on the 2024 and 2025 correspondence. Kaitlyn Clements appears as Regulatory Affairs Coordinator on a later submission. These are filing addresses and correspondents in FDA records, not a verified corporate headquarters. The filings name no parent company, brand owner or affiliate, so any ownership relationship beyond the named applicant is unknown. [6][8][9]

The clearances place the company's devices in Class II under regulation 21 CFR 878.4350, Cryosurgical Unit and Accessories. Product code GEH covers the CryoFreeze and Verruca-Freeze H clearances, while FreezeSpray TA carries product code MLY, classified as a vapocoolant device. The company's website describes its products as cryosurgical solutions for medical and veterinary professionals, a characterization published by the manufacturer rather than an FDA determination. [3][5][6][9]

Documented clearances and their scope

Verruca-Freeze H received clearance dated December 3, 2024, with the submission dated November 7, 2024. CryoFreeze Wart and Skin Tag Remover was cleared March 13, 2025, with the submission dated February 12, 2025. A second CryoFreeze submission, K253000, is dated September 16, 2025 and received September 18, 2025. The 2025 CryoFreeze summary describes the device as an over-the-counter cryosurgical device, with labeled uses covering common warts in adults and children age 4 years or older and over-the-counter treatment of skin tags in adults age 22 years or older. [6][8][9]

FreezeSpray TA, identified as K261684, was received May 21, 2026 and decided substantially equivalent on September 5, 2026, according to an FDA record indexed by FDA.report. That record lists product code MLY, device class U, a traditional clearance type and a summary, and states that the submission was not third-party reviewed. The indexed record also lists FDA registration number 1417592. The supplied collection contains one linked 510(k) record, the FreezeSpray TA entry, and its decision count shows one substantially equivalent decision; these figures describe the collection as of the snapshot date, not the company's total portfolio or sales. [1][5]

Products described in manufacturer documentation

The company's catalog lists Verruca-Freeze at a stated –70°C freezing temperature in kit configurations of 120ml, 135ml, 150ml and 175ml, alongside 150ml, 175ml and 236ml replacement canisters and a double kit with mixed applicators. The products page states that Verruca-Freeze H Plus is offered only in kit configurations, while the broader Verruca-Freeze line includes replacement canisters and accessories sold separately. The same page describes the –70°C temperature as intended for deep or calloused lesions such as plantar warts, a manufacturer statement about product positioning. [4][7]

The website promotes Verruca-Freeze H Plus as a colder, stronger freeze and lists an introductory offer for Histofreezer and qualifying competitor product users, with eligibility subject to verification and Histofreezer Flex excluded. A separate banner advertises a single kit at $99. These are the manufacturer's published commercial terms and may change; they are not evidence of clinical performance. [3]

What the record does not establish

The filings and website excerpts do not document independent clinical outcome data, certifications, customer lists or firsthand testing results. Clearance decisions establish regulatory marketing authorization for the described devices; they do not establish comparative efficacy against liquid nitrogen or other cryosurgical methods. The website's characterization of its devices as safe, effective and user-friendly is the manufacturer's own language. [3][6]

The company's known domain is not recorded in the supplied data, and the website content cited here comes from pages published under cryosurgeryinc.com. Details such as manufacturing sites beyond the listed registration number, distribution partners and international approvals are not documented in these sources and remain unknown. [3][5]